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Abstract 
Recruitment challenges to clinical research studies in palliative care settings, particularly in 
hospices, are well documented.  However, a recent study (Hospice Inpatient Deep vein 
thrombosis Detection Study (HIDDen)) performed across five hospices in the UK recruited 
above target and on time.  We describe strategies that aided successful recruitment in this 
study, and the lessons learnt for improving future studies.  A recent review suggested that the 
‘Social Marketing Mix Framework’ could help researchers with recruitment strategies in 
palliative care. We describe the recruiting strategies employed through the Social Marketing 
Mix lens and consider if it would be a useful framework for future researchers to use at the 
planning stage.  
Successful recruitment strategies employed in HIDDen included: i) addressing particular 
study related factors, ii) ensuring all patients were screened and offered participation if 
eligible, iii) reducing impact on the clinical team through dedicated research nurses at sites, 
iv) addressing research team issues with cross-cover between sites where geographically 
possible, and v) regular video conferencing meetings for support and collaborative solving of 
challenges. Limited pre-existing research infrastructure at most of the recruiting hospices 
created particular challenges.    
The Social Marketing Mix Framework provides a potential structure to help researchers plan 
recruitment.  However, to fully streamline trial set up and in order for hospice involvement in 
research to be realised systematically, a centralised approach to governance, organisational 
culture change whereby hospices embrace research as a legitimate purpose and consistent 
access to research staff, are identified as key strategic elements promoting recruitment to 
studies in hospices. 
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Key Statements 
What is already known about the topic? 
Research in palliative care, particularly in hospices is challenging with many studies failing 
to recruit successfully. 
What this paper adds 
This report illustrates that the use of the Social Marketing Mix Framework to inform 
recruitment strategies can facilitate hospice clinical studies. 
Implications for practice, theory or policy 
Incorporation of frameworks such as this when designing clinical studies in a hospice setting 
should improve recruitment.  
Introduction 
Compared with many other clinical specialties there are fewer clinical studies in palliative care.  
In order to obtain good translation from research into practice, clinical studies should be 
performed in a population that is representative of those in whom the intervention will be used. 
However, patients with poor performance status (ECOG>2) or estimated prognosis of less than 
three months are commonly excluded.  Patients requiring hospice in-patient admission often 
experience a wide variety of unstable physical and psychological symptoms.(1)  Few studies 
include patients with very advanced disease or who are hospice in-patients which limits 
generalisability to patients in this setting.(1)   
 
The many recruitment challenges in the palliative care setting are well documented (2-4) but 
not insurmountable. In addition to patient related factors including fatigue, limited prognosis 
etc., particular obstacles in the hospice setting include a lack of research infrastructure, aversion 
to perceived risk, few trained clinical researchers, prioritisation of clinical responsibilities, lack 
of protected research time, and funding difficulties especially as non-commercial research 
rarely generates income – a particular issue for many hospices which are funded independently. 
(5) 
 
Adequately powered palliative care clinical studies conducted solely in hospices are relatively 
few, with a recent review showing that only 10% of palliative and end of life studies conducted 
in Scotland (2006-2015) were undertaken in a hospice.(6)  Yet larger scale recruitment is 
possible.(7)  As studies in the hospice setting which have recruited either to, or above, target 
are infrequent, in this paper, we describe the recruitment strategies used in a successful 
prevalence cohort study which recruited 343 patients over 16 months from five hospice sites; 
the Hospice Inpatient Deep vein thrombosis (DVT) Detection Study (HIDDen).(8)  
Study assessments, including a bedside Doppler ultrasound scan, were conducted at baseline 
and then weekly for a maximum of three weeks or until discharge or death.  Ethical approval 
allowed immediate recruitment and consultee agreement if required and recruitment beyond 
the sample size based on the primary endpoint in order to increase precision around secondary 
endpoints.    From 1390 patients screened, 343 participants were recruited, which was above 
target (figure 1). Just over 60% (841) potential participants were ineligible, mostly due to an 
estimated prognosis of less than 5 days or being outside of the consent timeframe (within 48hrs 
of admission).  Less than a third (206) of those eligible declined participation. 
 
Figure 1 Predicted versus actual cumulative recruitment to HIDDen study 
INSERT FIGURE 1 
Strategies Used 
A recent review demonstrated the ‘Social Marketing Mix Framework’ (SMMF) could help 
guide researchers when planning and implementing recruitment strategies in palliative care, 
and hence improve recruitment to trials.(9)  The recruitment strategies used in this study are 
compared with SMMF principles (the 6 ‘Ps’)(9) to determine if these were employed in 
HIDDeN (Table 1), and might thus be a useful tool to guide those planning future studies 
wishing to emulate HIDDeN’s recruitment success. 
 
Table 1 Social Marketing Mix Framework (adapted from Dunleavy et al(9))  and 





(the 6 ‘Ps’) 
Definitions Strategies Used in HIDDen Study 
Identifying 
participants 
Defining the target audience • Wide inclusion criteria- all admissions who could have 
Doppler ultrasound 
• Minimal exclusion criteria- prognosis < 5 days, 
language issues, no consultee if lack of patient capacity 
• All patients screened on admission for eligibility – 
strategies implemented to ensure all were screened 
Product    
i) Defining the 
product 
The intervention is the product (its 
scientific, theoretical basis, does it 
meet the needs of the target 
audience?), the product must 
address a problem that is perceived 
as serious and amenable to the 
intervention 
• While there was no intervention in this study, 
identification of the clinical relevance of DVT was 
important in this setting  
o known to be important to patients 
o serious and amenable to intervention 
• Public and Patient Involvement (PPI) from the start of 




The amount of competition for the 
participant’s time and energy 
• Few or no competing clinical studies in recruiting units 
• 16 month recruitment period to maintain staff 
enthusiasm. 
Price The cost to the potential participant 
of taking part in the study (e.g. 
• No financial cost to patient 
• No travel or additional appointments required 
financial, time, physical and 
emotional effort). Things need to 
consider: type of costs and how to 
minimise the costs 
• Little physical effort for patient as study performed at 
patient’s bedside at a time convenient to them 
• Consent process was quick and immediate consent 
allowed – consultee agreement also allowed to reduce 
ineligibility with post hoc consent where possible  
• Short time requirement for involved patients once a 
week (10-20 mins maximum) 
• Very few questions asked to patients- information 




‘The location where the participant 
will receive information about, or 
engage in, the intervention’ 
• Patients all seen by their bedside at a time convenient 
to them. 
• Inpatient setting so more accessible than outpatient 
• Multiple recruitment sites with dedicated research 
nurse and clinical champion 
Promoting the 
study 
‘Identify the acceptable avenues that 
reach the target population’ 
• Education of all staff to reduce the risk of gatekeeping 
• Use of role-play for research nurses and clinical staff 
to ensure key messages given to patients in an 
understandable and consistent way. 
• Screening for recruitment had minimal impact on 
clinicians- less than two minutes per patient and 
minimal paperwork.  Consent process and data 
collection all done by dedicated research nurses. 
• Screening sheet included with medical admission pack 
to remind clinicians to screen all patient and involved 
brief tick box form for eligibility 
• Research nurses followed up any patients that had not 
been screened for eligibility within the recruitment 
timeframe with clinical staff where possible. 
• If patients were too symptomatic to discuss the study 
on the day of admission, permission was sought to 
return and discuss the trial the next day (if still within 
the recruitment period) – ‘respectful persistence’ 
Working With 
Partners 
‘Partners are defined as 
organisations involved with a social 
change effort or serving as conduits 
to target audiences’. Things to 
consider: partner education, partner 
referrals and recruitment and 
barriers to partnering. 
• Partnerships were formed with PPI representatives and 
the five hospice units involved  
• Research Ethics- significant effort was employed to 
ensure ethical issues were appropriately addressed.  
PPI representation helped facilitate this 
• Staff were educated about the trial and risks of 
gatekeeping to aid referrals to the research nurses 
• Good personal relationships between the research 
nurses and the clinical teams were fostered by repeated 
contact with referral sources 
• A Clinical Champion at each site encouraged 
recruitment 
• Resources- funded research nurses were employed at 
each site 
• Cross cover of sites by research nurses where 
geographically possible for leave and staff turnover. 
 
All strategies used had crucial input from service users and members of the public (Patient and 
Public Involvement [PPI]). Strategies included: 
i) Trial design factors –  
The trial had broad eligibility criteria with few criteria for exclusion; any adult being admitted 
to the hospice could be recruited so long as their prognosis was expected to be greater than five 
days. This made the screening process straightforward, reducing the burden on research nurses. 
A particular design strength was the inclusion of proxy consent for those unable to consent. 
This would include patients with hypercalcaemia, infection or opioid toxicity; all treatable yet 
highly thrombotic conditions which would have been lost to recruitment without proxy consent.   
PPI members gave specific advice on issues of recruitment, consent, sharing of Doppler 
ultrasound results and confirmed the importance of the research question. The high clinical 
relevance and importance to all patients facilitated maximum “buy-in” from staff, patients and 
carers.  
ii) Trial process factors  
Several strategies were employed to ensure identification of all eligible patients. In order to 
reduce gatekeeping, training was provided for all clinical staff regarding the importance of the 
research project. Patent screening sheets were inserted into the hospice admission packs to act 
as a prompt for the admitting clinician to screen and where appropriate ask permission for the 
research nurse to approach. In addition, there was daily research nurse follow up for those not 
screened to minimise missing eligible patients.  
iii) Trial conduct factors  
The trial was designed to confer minimal additional work on the clinical team and have little, 
if any, impact on the patient’s clinical care. This was facilitated by the presence of a dedicated 
research nurse who had no additional clinical commitments on the ward.  
iv) Research team issues – 
 The research nurses worked hard to develop a relationship with the clinical team, wherever 
possible ensuring a consistent presence in the hospice, which included attending team meetings 
and clinical handover.   Monthly face-to-face meetings between research nurses, using video 
conferencing to include those more distant helped support nurses working alone and address 
challenges faced. 
Challenges encountered 
Limited pre-existing research infrastructure at most of the individual hospices created a 
challenge.  Governance and paperwork processes differed among the sites (one NHS site, two 
Marie Curie voluntary sector hospices, two independent voluntary sector hospices). Only one 
site had a research nurse in post (Princess Alice, London). Another had a research nurse 
seconded from the local university (Cardiff), but the three Northern Ireland hospices had to 
recruit and employ research nurses for the first time. These different approaches were time 
consuming to negotiate.    
In the two sites that were geographically isolated, recruitment was not possible during periods 
of research nurse leave (annual and sick).  The three Northern Ireland sites were within a 25 
mile radius of each other, and so this was not an issue as the research nurses cross-covered the 
sites, greatly improving recruitment.  However, this meant all three nurses needed contracts 
and to meet the requirements at each of the three  sites (one NHS, one Marie Curie and one 
independent voluntary sector hospice) which was time consuming to set up. This included 
induction and mandatory training requirements at each site.  Funding was also needed for travel 
between sites, but this was built into the budget. 
Application 
The HIDDeN study has shown that a funded multisite study in UK hospices is possible and can 
recruit successfully to allow scientifically robust results.  Using the ‘6Ps’ of SMMF, successful 
recruitment strategies could be incorporated into study design and recruitment processes to 
help recruitment to time and target. This study showed that many hospice patients are willing 
to be involved in research even when in the last weeks of life, and the well-rehearsed challenges 
are not insurmountable. A systematic review and narrative analysis highlighted how palliative 
care researchers can learn from successful strategies in other “difficult-to-recruit” areas in 
healthcare such as delirium, dementia and emergency medicine. (10) It is important to consider 
our experiences in context; HIDDen was an observational study and it would presumptive to 
suggest the strategies reported would be sufficient to gain similar recruitment to a Clinical Trial 
of an Investigational Medicinal Product (CTIMP). Such trials may encroach more on staff time, 
particularly with respect to pharmacovigilance and the necessary approval and safety processes 
such as adverse event reporting.  Furthermore, it is possible that staff may be more reticent to 
flag up patients for a randomised interventional trial and patients may be reluctant to risk 
receiving placebo. However, such potential setbacks may be obviated by applying the 6Ps, with 
emphasis on “promoting the study”. This should focus on spending time to help the clinical 
team to understand the need for the trial and the concept of equipoise between the two trial 
arms. 
Implications for Research and Clinical Practice  
The importance of hospice involvement in research has been highlighted by Hospice UK (the 
national charity for UK hospice care).(11)  Multisite studies are required for timely recruitment 
and to increase generalisability of findings.  A centrally agreed and single governance process 
would be helpful in establishing hospice based research networks. Access to research nurses 
for hospices would greatly facilitate multisite research in the hospice setting. Maintenance of 
clinical services is the priority for most hospices and research nurses will usually need to be 
costed into grant applications.  In the UK, clinical research networks may support trials with 
network research nurses to assist recruitment and consent, but such nurses are very rarely 
attached to Hospices. The recent decision by the National Institute for Health Research in the 
UK that hospices were eligible to receive NHS Research Costs is an important step in the right 
direction. Hospices, from the management level to those delivering clinical services, must 
commit to having research as a core, legitimate purpose and to supporting regular research 
studies in order to maintain research nurse skills. 
 
Conclusions 
Research in hospices is vital to guide practice and improve patient care. While there are 
challenges, successfully run studies are possible when adequate attention, including PPI 
involvement, is given to addressing study design issues and recruitment strategies put in place.  
The SMMF provides one potential structure to address these issues.  The successful recruitment 
in the HIDDEN study(8) across five hospices in the UK demonstrates the value of the SMMF 
approach in planning Hospice based studies. However, in addition to such planning for studies 
in Hospice settings, a centralised approach to governance, a culture change whereby hospices 
embrace research as a legitimate purpose, and employment of (or consistent access to) research 
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